{"id":67898,"date":"2023-10-02T13:54:41","date_gmt":"2023-10-02T17:54:41","guid":{"rendered":"https:\/\/ifintechworld.com\/news\/lexeo-therapeutics-starts-100-million-u-s-ipo-effort-pendinglxeo\/"},"modified":"2023-10-02T13:54:47","modified_gmt":"2023-10-02T17:54:47","slug":"lexeo-therapeutics-starts-100-million-u-s-ipo-effort-pendinglxeo","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=67898","title":{"rendered":"Lexeo Therapeutics Starts $100 Million U.S. IPO Effort (Pending:LXEO)"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

A Quick Take On Lexeo Therapeutics, Inc.<\/h2>\n

Lexeo Therapeutics, Inc.<\/b> (LXEO) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.<\/p>\n

The clinical-stage biopharma is developing treatments for various cardiovascular and Alzheimer’s conditions.<\/span><\/p>\n

When we learn more about management’s pricing and valuation assumptions, I’ll provide a final opinion.<\/p>\n

Lexeo Overview<\/h2>\n

New York, NY-based Lexeo Therapeutics, Inc. was founded to develop drug treatment candidates for various cardiovascular and neurological diseases.<\/p>\n

Management is headed by Chief Executive Officer R. Nolan Townsend, who has been with the firm since 2020 and was previously at Pfizer where he was President of Pfizer Rare Disease for the North America region.<\/p>\n

The firm’s lead candidate, LX2006, is currently in Phase 1\/2 clinical trials for the treatment of Friedreich’s ataxia.<\/p>\n

The company expects to report interim data from the LX2006 trial in mid-2024.<\/span><\/p>\n

Below is the current status of the company’s drug development pipeline:<\/p>\n

\n

\"Company<\/picture>
\n

Company Pipeline (Lexeo Website)<\/p>\n<\/figcaption><\/figure>\n<\/p>\n

Lexeo has booked a fair market value investment of $189 million as of June 30, 2023, from investors, including D1, PBM LEX Holdings, Janus Henderson, Longitude Venture Partners, Lundbeckfond Invest, Eventide Healthcare & Life Sciences Fund, Omega Fund and Ronald G. Crystal, MD and affiliates.<\/p>\n

Lexeo’s Market & Competition<\/h2>\n

According to a 2022 market research report by Coherent Market Insights, the worldwide market for treatments for Friedreich’s ataxia is estimated at $777 million in 2022 and is forecast to reach $2.06 billion in 2030.<\/p>\n

This represents an expected CAGR (Compound Annual Growth Rate) of CAGR of 13.0% from 2022 to 2030.<\/p>\n

Key elements driving this expected growth are the continued development of approved treatment options along with inorganic business collaborations and acquisitions.<\/p>\n

Also, by region, North America is expected to hold the largest demand for treatments during the forecast period through 2030.<\/p>\n

The company is pursuing drug treatment testing for other multi-billion dollar size markets.<\/p>\n

Major competitive vendors that provide or are developing related treatments include:<\/p>\n